CD19 and Miyoshi myopathy: In pre-clinical models, this ADC targets bulk MM cells as well as patient MM progenitor cells that are CD19 + CD138- and kills cells by inducing multiple DNA damage response genes via phosphorylating ATM/ATR kinases, checkpoint kinases 1/2 (CHK1/2), and H2AX regardless of p53 status [79].